期刊
OPEN FORUM INFECTIOUS DISEASES
卷 9, 期 5, 页码 -出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac179
关键词
COVID-19; SARS-CoV-2; procalcitonin; coinfection
资金
- National Institute for Health Research (NIHR) [CO-CIN-01]
- Medical Research Council [MC_PC_19059]
- NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool
- Public Health England (PHE) [200927]
- Wellcome Trust [215091/Z/18/Z]
- Department for International Development [215091/Z/18/Z]
- Bill and Melinda Gates Foundation [OPP1209135]
- Liverpool Experimental Cancer Medicine Centre [C18616/A25153]
- NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]
- EU Platform for European Preparedness Against (Re-) emerging Epidemics (FP7 project) [602525]
- Wellcome Trust fellowship [205228/Z/16/Z]
- NIHR Senior Investigator Award [201385]
- Liverpool School of Tropical Medicine
- University of Oxford [200907]
- Bill and Melinda Gates Foundation [OPP1209135] Funding Source: Bill and Melinda Gates Foundation
- National Institutes of Health Research (NIHR) [IS-BRC-1215-20013] Funding Source: National Institutes of Health Research (NIHR)
Procalcitonin measurements and microbiology results were not clinically significant or diagnostically useful for bacterial coinfection in hospitalized adults with coronavirus disease 2019.
Admission procalcitonin measurements and microbiology results were available for 1040 hospitalized adults with coronavirus disease 2019 (from 48 902 included in the International Severe Acute Respiratory and Emerging Infections Consortium World Health Organization Clinical Characterisation Protocol UK study). Although procalcitonin was higher in bacterial coinfection, this was neither clinically significant (median [IQR], 0.33 [0.11-1.70] ng/mL vs 0.24 [0.10-0.90] ng/mL) nor diagnostically useful (area under the receiver operating characteristic curve, 0.56 [95% confidence interval, .51-.60]).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
